Serum Advanced Glycation End Products and Their Soluble Receptor as New Biomarkers in Systemic Lupus Erythematosus
Carrión-Barberà, Irene (Institut Hospital del Mar d'Investigacions Mèdiques)
Triginer, Laura (Institut Hospital del Mar d'Investigacions Mèdiques)
Tío Barrera, Laura (Institut Hospital del Mar d'Investigacions Mèdiques)
Pérez-García, Carolina (Hospital del Mar (Barcelona, Catalunya))
Ribes, Anna (Institut Hospital del Mar d'Investigacions Mèdiques)
Abad, Victoria (Hospital del Mar (Barcelona, Catalunya))
Pros, Ana (Hospital del Mar (Barcelona, Catalunya))
Monfort, Jordi (Institut Hospital del Mar d'Investigacions Mèdiques)
Salman-Monte, Tarek Carlos (Institut Hospital del Mar d'Investigacions Mèdiques)
Universitat Autònoma de Barcelona

Date:	2024
Abstract:	It has been postulated that advanced glycation end products (AGEs) and their soluble receptor (sRAGE) may play a relevant role as inducers in the chronic inflammatory pathway in various conditions, among them, in immune-mediated diseases such as systemic lupus erythematosus (SLE). However, previous studies show conflicting results about their association with SLE characteristics and their usefulness as disease biomarkers. We aimed to study the association of specific serum AGEs (pentosidine, Nξ-(carboxymethyl)lysine (CML), Nξ-(carboxyethyl)lysine (CEL)), sRAGE levels and AGEs (specific serum AGEs and skin AGEs) to sRAGE ratios with various disease parameters, in order to clarify their potential as new biomarkers in SLE and to study their relationship with cardiovascular disease (CVD). To this aim, serum pentosidine, CML, CEL and sRAGE were measured via ELISA, and skin AGEs levels were measured by skin autofluorescence. Correlations of pentosidine levels with demographic and clinical data, indexes of activity, accrual damage and patient-reported outcomes were analyzed through multiple linear regression models, while correlations of the rest of the AGEs, sRAGE and AGE to sRAGE ratios (non-normal) were analyzed using both an OLS regression model and a GML. All of the analyses were adjusted for confounders. A total of 119 SLE patients were recruited. Serum AGEs and sRAGEs were significantly associated with SLE activity indexes and/or demographic or disease characteristics: pentosidine with pulmonary manifestations; CML with anti-dsDNA antibodies, IL-6, disease duration and non-Caucasian ethnicities; CEL with anti-dsDNA antibodies, IL-6 and accumulated number of manifestations; and sRAGE with male gender, photosensitivity and being on specific immunosuppressants. These results suggest that the AGE-sRAGE axis may serve as a novel biomarker for managing and prognosticating this disease. Its correlation with certain antibodies, demographics and disease presentations may indicate a distinct clinical phenotype associated with varying levels of AGEs and/or sRAGE. The significance of specific AGE/sRAGE ratios, introduced in this study for the first time, warrants additional investigation in forthcoming research. Our study did not confirm the link between serum AGEs and CVD, which merits further exploration through studies designed for this specific purpose.
Grants:	Instituto de Salud Carlos III PI18/00059
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Activity index ; Advanced glycation end products ; Cardiovascular disease ; Systemic lupus erythematosus
Published in:	Biomedicines, Vol. 12 (march 2024) , ISSN 2227-9059

DOI: 10.3390/biomedicines12030610
PMID: 38540223

25 p, 2.1 MB

The record appears in these collections:
Articles > Research articles
Articles > Published articles